M. Sample 13) European American smokers who successfully vs unsuccessfully quit smoking in trials in North Carolina: Participants received either active 21 mg/day or placebo nicotine skin patches for two weeks before the targeted quit date as well as mecamylamine 10 mg/day po prior to the target quit-smoking date [120]. After the quit-date, participants were randomly assigned to mecamylamine 10 mg/day vs matching placebo and 21 mg/24 h vs 42 mg/24 h nicotine skin patch doses. Fifty-five individuals reported continuous abstinence from smoking when assessed 6 weeks after the quit date with biochemical confirmation; 79 were not abstinent.
